The short answer
The sources checked do not establish that soy-isoflavone supplements reduce liothyronine absorption. A small study of a specific isoflavone product found no effect on levothyroxine absorption, while separate studies of thyroid function had mixed results. Neither finding settles this exact T3 combination.
What this answer covers
Oral liothyronine and soy-isoflavone supplements. Soy foods, soybean flour and soy-protein products differ from isolated isoflavones; levothyroxine studies are indirect.
- Supplement or preparation
- Soy Isoflavones
- Medication ingredient
- liothyronine
What is the most relevant absorption study?
Twelve postmenopausal women on levothyroxine took a 60 mg soy-isoflavone combination either at the same time as their medicine or six hours later. The measured T4 absorption was equivalent between schedules. This is contrary evidence for a blanket isoflavone warning, but it did not test liothyronine.
Have thyroid-function changes been reported?
Yes, some isoflavone trials reported changes in TSH, FT4 or reverse T3, while a study in healthy young men found no significant thyroid-hormone change. These studies used specific soy preparations without administered liothyronine. A change in endogenous hormone tests is not proof that a T3 tablet was poorly absorbed.
Should soy foods and isoflavone capsules be treated alike?
No. The protein, fiber and isoflavone content differ between foods, protein powders and concentrated extracts. A warning derived from soy protein or infant formula should not automatically be applied to every isoflavone product. Record the actual preparation and dose for review.
Is there an established T3 timing rule?
No fixed interval was established for this exact pair. Discuss starting or stopping a regular isoflavone supplement with the prescriber, especially if thyroid tests change. If levothyroxine is also part of treatment, follow its product-specific instructions separately.
Evidence and practical considerations
Absorption & effectiveness
The sources checked do not establish that soy-isoflavone supplements reduce liothyronine absorption. A small study of a specific isoflavone product found no effect on levothyroxine absorption, while separate studies of thyroid function had mixed results. Neither finding settles this exact T3 combination.
- Exact scope
- Oral liothyronine and soy-isoflavone supplements. Soy foods, soybean flour and soy-protein products differ from isolated isoflavones; levothyroxine studies are indirect. with oral liothyronine sodium providing the exact liothyronine active moiety
- Medication form and route
- oral
- Timing or duration
- During co-use; study-specific durations are retained in the source summaries. No universal duration or dose-response inferred.
What remains uncertain
- No direct liothyronine co-use trial; a negative T4 absorption study and heterogeneous supplement-only endocrine findings do not establish either safety or reduced T3 absorption.
Factors that may matter: exact supplement preparation and dose; oral versus nonoral medication route; other formula ingredients; patient thyroid status.
Read the supporting source summaries
Source 1: regulatory product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed oral liothyronine sodium tablets.
T3 dose depends on food, other medicines, clinical response and laboratory results. Table 1 explicitly names resins and bile-acid sequestrants, but does not name the mineral, fiber, soy or botanical pairs evaluated here.
How this applies: Confirms exact liothyronine active moiety, not levothyroxine. Supports monitored individualized treatment; mineral and botanical conclusions require other sources. Exact package scope: Oral liothyronine and soy-isoflavone supplements. Soy foods, soybean flour and soy-protein products differ from isolated isoflavones; levothyroxine studies are indirect.
Absence of a named interaction is not evidence of absence. The four-hour resin instruction cannot automatically be transferred to minerals or fiber.
Source 2: randomized crossover pharmacokinetic study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Twelve postmenopausal women on stable levothyroxine.
T4 peak-concentration and exposure ratios were 1.02 and 0.99; confidence intervals met the prespecified equivalence limits.
How this applies: Contrary indirect evidence: a specific isoflavone preparation did not impair T4 absorption. Soy food/protein warnings cannot simply be assigned to soy isoflavones with T3. Exact package scope: Oral liothyronine and soy-isoflavone supplements. Soy foods, soybean flour and soy-protein products differ from isolated isoflavones; levothyroxine studies are indirect.
Single fixed formulation, small study, T4 rather than liothyronine. Does not clear all soy supplements.
Source 3: randomized crossover dietary study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Thirty-five healthy young men.
No significant difference in thyroid hormones or TSH between preparations.
How this applies: Contrary supplement-only thyroid-function evidence, not a drug-absorption test. Exact package scope: Oral liothyronine and soy-isoflavone supplements. Soy foods, soybean flour and soy-protein products differ from isolated isoflavones; levothyroxine studies are indirect.
Protein matrix, healthy men, no liothyronine therapy. Does not exclude effects in thyroid disease or other preparations.
Source 4: analysis of two randomized dietary trials
pmc.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Two trials totaling 400 euthyroid adults: men with type 2 diabetes and postmenopausal women.
At three months, TSH and reverse T3 increased while FT4 decreased; FT3 did not differ. Reverse T3 changes were not sustained at six months.
How this applies: Retains potentially adverse physiologic evidence alongside negative studies while keeping it separate from the exact T3 absorption claim. Exact package scope: Oral liothyronine and soy-isoflavone supplements. Soy foods, soybean flour and soy-protein products differ from isolated isoflavones; levothyroxine studies are indirect.
No administered liothyronine; hormone biomarkers do not establish reduced medication absorption or clinical harm.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Removes the unqualified reduction claim, preserves the negative isoflavone/T4 trial and distinguishes absorption from thyroid-function findings. | |
| Research summary published |
Article revision: aa61698b562205f2
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.